Insights

Gathering insights about TenX…

Similar companies to TenX

TenX Tech Stack

TenX uses 8 technology products and services including Gradle, GDPR, SonarQube, and more. Explore TenX's tech stack below.

Gradle
Build Automation
GDPR
Certificates
SonarQube
Development
Lightbox
Javascript Libraries
Elementor
Page Builders
Google Analytics
Web Analytics
OceanWP
Web Platform Extensions
Nginx
Web Servers

Media & News

Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200 Day Moving Average – What’s Next?
Shares of Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $6.85 and traded as high as $12.42. Tenax Therapeutics shares last traded at $11.79, with a volume of 358,446 shares traded. Analyst
Dec 18, 2025 | www.defenseworld.net
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of Enrollment by End of 2027 CHAPEL HILL, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the prespecified Blinded Sample Size Re-estimation (BSSR) of LEVEL demonstrated the trial is powered at well over 90% to detect a 25 meter change in 6-minute walk distance (6MWD), the primary endpoint.
Dec 17, 2025 | www.globenewswire.com
Tenax Therapeutics to Participate in Upcoming Investor Conferences
CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the following investor conferences:
Nov 25, 2025 | www.globenewswire.com
Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript
Tenax Therapeutics, Inc. ( TENX ) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF November 13, 2025 4:30 PM EST Company Participants Christopher Giordano - CEO, President & Director Stuart Rich - Chief Medical Officer & Director Sanjiv Shah Barry Borlaug Conference Call Participants David Risinger - Leerink Partners LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, and welcome to the Tenax Therapeutics Virtual KOL Call.
Nov 13, 2025 | seekingalpha.com
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026
Nov 12, 2025 | www.globenewswire.com
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will host a conference call and webcast on Thursday, November 13, 2025, at 4:30 p.m.
Nov 06, 2025 | www.globenewswire.com
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA.
Nov 03, 2025 | www.globenewswire.com

TenX's Email Address Formats

TenX uses at least 2 format(s):

TenX Email Formats	Example	Percentage
First.Last@analytics.com.pk	John.Doe@analytics.com.pk	96%
First.Middle@analytics.com.pk	John.Michael@analytics.com.pk	4%
First@tenx.ai	John@tenx.ai	71%
First.Last@tenx.ai	John.Doe@tenx.ai	29%

Frequently Asked Questions

What is TenX's stock symbol?

TenX is a publicly traded company; the company's stock symbol is TENX.

What is TenX's official website and social media links?

TenX's official website is tenx.ai and has social profiles on LinkedIn.

What is TenX's NAICS code?

TenX's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does TenX have currently?

As of December 2025, TenX has approximately 219 employees across 6 continents, including AsiaNorth AmericaEurope. Key team members include Chief Executive Officer: Q. Q.Vice President Of International Sales: W. A. Q.Vice President Engineering: B. X.. Explore TenX's employee directory with LeadIQ.

What industry does TenX belong to?

TenX operates in the IT Services and IT Consulting industry.

What technology does TenX use?

TenX's tech stack includes GradleGDPRSonarQubeLightboxElementorGoogle AnalyticsOceanWPNginx.

What is TenX's email format?

TenX's email format typically follows the pattern of First.Last@analytics.com.pk. Find more TenX email formats with LeadIQ.

When was TenX founded?

TenX was founded in 2015.

TenX

Q: What is TenX's official website and social media links?

TenX's official website is tenx.ai. TenX has social profiles on LinkedIn.

Q: How many employees does TenX have currently?

TenX has approximately 219 employees.

Q: What technology does TenX use?

TenX's tech stack includes Swiper, X-Content-Type-Options, X-UA-Compatible, Microsoft 365, Microsoft Azure.

IT Services and IT ConsultingConnecticut, United States201-500 Employees

As a global tech agency, we operate as a service provider, product lab, and strategic investor, collaborating with businesses to fuel growth. Focused on business results, we've consistently delivered powerful solutions, achieving global success with clients ranging from ambitious startups to Fortune 500 companies.